News

FDA approves Merck’s RSV shot for infants, ramping up competition with Sanofi and AstraZeneca
Merck's shot will compete against a similar blockbuster treatment from Sanofi and AstraZeneca called Beyfortus.
CIDRAP9d
FDA approves Merck RSV monoclonal antibody shot for infants
Merck announced yesterday that the US Food and Drug Administration (FDA) has approved its monoclonal antibody vaccine ...
PharmExec6d
FDA Approves Expanded Indication for Moderna’s Respiratory Syncytial Virus Vaccine mRESVIA
RESVIA is now authorized for use in adults aged 18–59 years with an increased risk of respiratory syncytial virus-related ...
MedCity News10d
Merck RSV Drug for Infants Wins FDA Nod, But CDC Committee That Will Advise on Its Use Is Gutted
A Merck drug developed to prevent disease from respiratory syncytial virus (RSV) in infants has won FDA ... vaccine comprised of an engineered version of RSV F protein antigen. It was first ...
BioPharma Dive10d
Merck antibody drug for RSV approved by FDA
Known as Enflonsia, the drug will compete for market share with Sanofi and AstraZeneca’s in-demand Beyfortus, which quickly ...
Fierce Pharma10d
Merck scores FDA nod for Enflonsia, setting up RSV market battle vs. Sanofi and AstraZeneca's Beyfortus
Meanwhile, Sanofi has pointed to Beyfortus’ 75% reduction in the incidence of MALRI versus Enflosia’s figure of 60%. The ...
Healio9d
FDA approves clesrovimab for preventing RSV in infants
The FDA approved the monoclonal antibody clesrovimab-cfor for the prevention of respiratory syncytial virus lower respiratory ...
fox17online7d
FDA approves Merck’s Enflonsia to prevent RSV in infants
The Food and Drug Administration has approved a new drug from Merck designed to protect infants ... their mothers did not receive a maternal RSV vaccine.